Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bafna PharmaceuticalsNSE:BAFNAPH -2.00%60 Cash Ratio is 0.07 as of Mar. 2026, which is 40% above its 10-year median of 0.05. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 60/100 and a GF Value™ of ₹91.24 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 974 Drug Manufacturers companies, Bafna Pharmaceuticals ranks worse than 86.86% on this metric.
Bafna Pharmaceuticals has a Cash Ratio of 0.07. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Bafna Pharmaceuticals's Cash Ratio or its related term are showing as below:
NSE:BAFNAPH'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.05 Max: 0.48
Current: 0.07
During the past 13 years, Bafna Pharmaceuticals's highest Cash Ratio was 0.48. The lowest was 0.01. And the median was 0.05.
NSE:BAFNAPH's Cash Ratio is ranked worse than 86.86% of 974
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs NSE:BAFNAPH: 0.07
Bafna Pharmaceuticals (NSE:BAFNAPH) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bafna Pharmaceuticals Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Bafna Pharmaceuticals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bafna Pharmaceuticals (NSE:BAFNAPH) has a Cash Ratio of 0.07 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Bafna Pharmaceuticals and its competitors. This is 40% above median its historical median of 0.05. Over the past decade, Bafna Pharmaceuticals' Cash Ratio has ranged from 0.01 to 0.48. According to the industry distribution chart, Bafna Pharmaceuticals ranks #846 out of 974 companies in the Drug Manufacturers industry, placing it in the top 86.9%.
Is Bafna Pharmaceuticals' Cash Ratio too high?
Bafna Pharmaceuticals' current Cash Ratio of 0.07 is 40% above median its 10-year median of 0.05. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.48. The Drug Manufacturers industry median Cash Ratio is 0.61. Bafna Pharmaceuticals' value of 0.07 is 88.5% below this industry median. Based on the distribution chart, Bafna Pharmaceuticals ranks #846 out of 974 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bafna Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' Cash Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #846 out of 974 companies for Cash Ratio. This places Bafna Pharmaceuticals in the lower half of its industry. The industry median Cash Ratio is 0.61. Bafna Pharmaceuticals' value of 0.07 is 88.5% below this benchmark. Historically, Bafna Pharmaceuticals' own Cash Ratio has ranged from 0.01 to 0.48 over the past decade. While the company's 10-year median is 0.05 vs. the industry median of 0.61, Bafna Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.61, based on 974 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bafna Pharmaceuticals's current Cash Ratio of 0.07 is 88.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Bafna Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current Cash Ratio is 0.07, which is 40% above median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹91.24, compared to a current price of ₹238.15 — trading 161% above its estimated fair value. The current Cash Ratio is 0.07, which is 40% above median its 10-year median of 0.05 and 88.5% below the Drug Manufacturers industry median of 0.61. Bafna Pharmaceuticals' overall GF Score™ is 60/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current Cash Ratio is 0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹238.15 is trading 161% above its estimated GF Value™ of ₹91.24.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
Cash Ratio: 0.07 (40% above median its 10-year median of 0.05)
GF Value™: ₹91.24 vs. price of ₹238.15 (161% above fair value)
Industry Position: 88.5% below the Drug Manufacturers median (#846 of 974)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
60GF Score
Get the complete analysis for NSE:BAFNAPH
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 
